Clinical usefulness of the free web-based image analysis application ImmunoRatio for assessment of Ki-67 labelling index in breast cancer

Journal of Clinical Pathology

Volumn 70, Issue 8, 2017, Pages 715-719

  Yeo, Min Kyung ^a,b   Kim, Hee Eun ^a   Kim, Sung Hun ^c   Chae, Byung Joo ^c   Song, Byung Joo ^c   Lee, Ahwon ^a  

^a The Catholic University of Korea   (South Korea)

^b Chungnam National University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

BREAST CANCER; DIGITAL PATHOLOGY; PROLIFERATION

Indexed keywords

HORMONE RECEPTOR; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERNET; KAPLAN MEIER METHOD; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; BREAST TUMOR; EVALUATION STUDY; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INTERNET; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 85025071020     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2016-204162     Document Type: Article

References (16)

1. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-64.
2. De Azambuja E, Cardoso F, de Castro G, et al. Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12, 155 patients. Br J Cancer 2007;96:1504-13.
3. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569-75.
4. Guarneri V, Piacentini F, Ficarra G, et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009;20:1193-8.
5. Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011;11:486.
6. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
7. Tuominen VJ, Ruotoistenmäki S, Viitanen A, et al. ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010;12:R56.
8. Gudlaugsson E, Skaland I, Janssen EA, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology 2012;61:1134-44.
9. Cho U, Kim HE, Oh WJ, et al. The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value. Appl Immunohistochem Mol Morphol 2016;24:159-66.
10. Guiu S, Michiels S, André F, et al. Molecular subclasses of breast cancer: how do we define them The IMPAKT 2012 Working Group Statement. Ann Oncol 2012;23:2997-3006.
11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
12. Klintman M, Bendahl PO, Grabau D, et al. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 2010;23:251-9.
13. Pellikainen MJ, Pekola TT, Ropponen KM, et al. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003;56:214-20.
14. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
15. Focke CM, Decker T, van Diest PJ. Reliability of the Ki67-labelling index in core needle biopsies of luminal breast cancers is unaffected by biopsy volume. Ann Surg Oncol. Published Online First: 22 Dec 2016. doi:10. 1245/s10434-016-5730-1.
16. Sundara Rajan S, Horgan K, Speirs V, et al. External validation of the ImmunoRatio image analysis application for ER determination in breast cancer. J Clin Pathol 2013;67:72-5.